Objective: Screening plasma samples from patients with sporadic Creutzfeldt-Jakob disease (CJD) to discover diagnostic biomarkers. Methods: Plasma samples were collected from 17 patients with sporadic CJD, 17 patients with Alzheimer disease (AD), and 20 healthy subjects. A 2-phase screening was carried out using quantitative protein mass spectrometry. The putative sporadic CJD biomarkers were then validated independently by immunoturbidimetry. Results: Mass spectrometry uncovered 7 candidate sporadic CJD protein biomarkers, all belonging to the acute-phase response. Highly significant increases of these markers in patients with sporadic CJD, compared with healthy subjects and patients with AD, was confirmed by immunoturbidimetry. Conclusions: The increase in plasma levels of a related set of acute-phase reactants in patients with sporadic CJD is a novel finding that suggests new pathogenetic hypotheses. The possible value of this set of proteins as biomarkers in the diagnosis of sporadic CJD or for blood/tissue donor screening remains to be further explored and validated in larger studies. Neurology (R) 2012;79:1012-1018
Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD / F., Fratini; S., Principe; M., Puopolo; A., Ladogana; A., Poleggi; P., Piscopo; Bruno, Giuseppe; S., Castrechini; Pascone, Roberto; A., Confaloni; L., Minghetti; F., Cardone; M., Pocchiari; M., Crescenzi. - In: NEUROLOGY. - ISSN 0028-3878. - 79:10(2012), pp. 1012-1018. [10.1212/wnl.0b013e318265a55d]
Increased levels of acute-phase inflammatory proteins in plasma of patients with sporadic CJD
BRUNO, Giuseppe;PASCONE, Roberto;
2012
Abstract
Objective: Screening plasma samples from patients with sporadic Creutzfeldt-Jakob disease (CJD) to discover diagnostic biomarkers. Methods: Plasma samples were collected from 17 patients with sporadic CJD, 17 patients with Alzheimer disease (AD), and 20 healthy subjects. A 2-phase screening was carried out using quantitative protein mass spectrometry. The putative sporadic CJD biomarkers were then validated independently by immunoturbidimetry. Results: Mass spectrometry uncovered 7 candidate sporadic CJD protein biomarkers, all belonging to the acute-phase response. Highly significant increases of these markers in patients with sporadic CJD, compared with healthy subjects and patients with AD, was confirmed by immunoturbidimetry. Conclusions: The increase in plasma levels of a related set of acute-phase reactants in patients with sporadic CJD is a novel finding that suggests new pathogenetic hypotheses. The possible value of this set of proteins as biomarkers in the diagnosis of sporadic CJD or for blood/tissue donor screening remains to be further explored and validated in larger studies. Neurology (R) 2012;79:1012-1018I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
